Sun Pharma Names Kirti Ganorkar as Managing Director in Leadership Overhaul

Kirti Ganorkar at Sun Pharmaceutical has been leading the India business at Sun Pharma since June 2019. Abhay Gandhi, President and CEO of North America, has decided to pursue his interests outside Sun Pharma.

Sun Pharmaceutical Industries Ltd, India's largest pharmaceutical company by revenue, has appointed Kirti Ganorkar as its managing director, effective 1 September 2025, marking a key leadership transition in one of the country's most influential healthcare firms.

The appointment, announced on Friday, follows a board decision to elevate Ganorkar for a five-year term, subject to shareholder approval at the company’s Annual General Meeting scheduled for 31 July 2025.

Who Is Kirti Ganorkar?

Kirti Ganorkar is a seasoned leader with a rich history at Sun Pharma. He joined the company in 1996 and has since held various key roles across business development, marketing, mergers and acquisitions, new product introduction, project management, intellectual property, and litigation. Ganorkar is a chemical engineer by training and also holds an MBA, equipping him with a strong foundation for both technical and business leadership.

Since June 2019, Kirti Ganorkar has been leading Sun Pharma’s India business, under whose stewardship the company’s market share and operational performance have seen consistent growth. His leadership has been instrumental in driving Sun Pharma’s foray into specialty pharmaceuticals, notably securing rights for innovative products such as Ilumya. Ganorkar also played a crucial role in Sun Pharma’s entry into Japan and laid the groundwork for its expansion into Europe, while supporting key generic projects in the US market from concept to commercialization.